Henry Schein, Inc. (NASDAQ:HSIC - Get Free Report) Director Philip A. Laskawy sold 2,604 shares of the firm's stock in a transaction dated Wednesday, March 19th. The shares were sold at an average price of $71.04, for a total transaction of $184,988.16. Following the completion of the sale, the director now owns 24,805 shares of the company's stock, valued at $1,762,147.20. The trade was a 9.50 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link.
Henry Schein Trading Up 2.0 %
NASDAQ HSIC traded up $1.37 during trading hours on Monday, hitting $70.76. 779,046 shares of the company's stock were exchanged, compared to its average volume of 1,508,752. The firm has a market cap of $8.79 billion, a price-to-earnings ratio of 29.12, a PEG ratio of 2.13 and a beta of 0.90. The stock has a 50-day simple moving average of $74.82 and a 200 day simple moving average of $72.64. The company has a current ratio of 1.42, a quick ratio of 0.82 and a debt-to-equity ratio of 0.46. Henry Schein, Inc. has a 1-year low of $63.67 and a 1-year high of $82.49.
Henry Schein (NASDAQ:HSIC - Get Free Report) last released its quarterly earnings data on Tuesday, February 25th. The company reported $1.19 EPS for the quarter, missing the consensus estimate of $1.23 by ($0.04). The firm had revenue of $3.19 billion for the quarter, compared to the consensus estimate of $3.25 billion. Henry Schein had a net margin of 2.51% and a return on equity of 12.90%. The company's revenue was up 5.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.66 EPS. On average, equities analysts forecast that Henry Schein, Inc. will post 4.74 EPS for the current fiscal year.
Analyst Ratings Changes
Several equities research analysts recently commented on HSIC shares. Barrington Research reaffirmed an "outperform" rating and issued a $90.00 price objective on shares of Henry Schein in a research report on Wednesday, February 26th. UBS Group reduced their target price on shares of Henry Schein from $83.00 to $80.00 and set a "neutral" rating for the company in a report on Wednesday, February 26th. Bank of America upgraded shares of Henry Schein from an "underperform" rating to a "buy" rating and upped their price target for the company from $69.00 to $84.00 in a research note on Monday, January 6th. Mizuho started coverage on Henry Schein in a research report on Wednesday, December 4th. They set a "neutral" rating and a $75.00 target price for the company. Finally, Jefferies Financial Group lifted their price target on Henry Schein from $77.00 to $80.00 and gave the company a "hold" rating in a research note on Thursday, January 23rd. Six analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $81.10.
View Our Latest Analysis on Henry Schein
Institutional Inflows and Outflows
A number of hedge funds have recently added to or reduced their stakes in the stock. Smartleaf Asset Management LLC grew its position in shares of Henry Schein by 23.2% during the 4th quarter. Smartleaf Asset Management LLC now owns 759 shares of the company's stock valued at $52,000 after purchasing an additional 143 shares in the last quarter. Guggenheim Capital LLC grew its position in Henry Schein by 2.5% during the fourth quarter. Guggenheim Capital LLC now owns 6,428 shares of the company's stock worth $445,000 after buying an additional 159 shares in the last quarter. CIBC Asset Management Inc increased its stake in Henry Schein by 1.0% in the 4th quarter. CIBC Asset Management Inc now owns 17,849 shares of the company's stock worth $1,235,000 after acquiring an additional 169 shares during the last quarter. Studio Investment Management LLC raised its holdings in shares of Henry Schein by 3.8% in the 3rd quarter. Studio Investment Management LLC now owns 4,674 shares of the company's stock valued at $341,000 after acquiring an additional 172 shares in the last quarter. Finally, Metis Global Partners LLC grew its holdings in shares of Henry Schein by 4.7% during the fourth quarter. Metis Global Partners LLC now owns 4,203 shares of the company's stock worth $291,000 after purchasing an additional 187 shares in the last quarter. Hedge funds and other institutional investors own 96.62% of the company's stock.
About Henry Schein
(
Get Free Report)
Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.
Read More
Before you consider Henry Schein, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Henry Schein wasn't on the list.
While Henry Schein currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
